Recent market shifts indicate a more favorable climate ahead for the biotechnology industry. With interest rate cuts anticipated later this year, biotech stocks are well-positioned for a resurgence in investor interest. This is particularly true within niche sectors like therapies for hereditary angioedema (HAE), a genetic condition causing potentially dangerous swelling. Citi analysts have pinpointed … Biotech Sector Poised for Renewed Growth as Interest Rates Cool
The post Biotech Sector Poised for Renewed Growth as Interest Rates Cool appeared first on ImaStockTrader.